ClinicalTrials.gg
RecruitingNCT06917131Updated May 19, 2026

Royal Jelly as a Strategy to Modulate Inflammation and Oxidative Stress in Patients With Systemic Arterial Hypertension

An interventional study of Royal Jelly and Placebo in Hypertension, Cardiovascular Diseases (CVD) and Inflammation, sponsored by Universidade Federal Fluminense. Recruiting at 1 site in Brazil. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-19.

Sponsored by Universidade Federal Fluminense · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Sep 2024, registered Apr 2025).
  • Started Sep 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 209 studies in Hypertension with a site in Brazil — 28 open to participants now, 33 under way, 6 of them phase 3. Hypertension · Brazil.

Planned enrollment
151st of 189
34 · median 80
Started
2024
with 11 others
No phase
112 of 209
15 open now
Primary completion
2026-12
later than 10 of 32 live
Registered
192nd of 209
by date

Among the 209 studies in Hypertension with a site in Brazil, this one is the 151st largest by planned enrollment of the 189 interventional ones that give a count, is one of 12 that started in 2024, is one of 112 with no phase, reaches primary completion later than 10 of the 32 other live ones, and was the 192nd registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

28 of the 209 studies in Hypertension with a site in Brazil are open now. Recruiting first, the newest first:

22 more — sign in →

All 28 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 209 studies in Hypertension with a site in Brazil, or all of them as a file.
02

Study summary

The study aims to evaluate the effect of the royal jelly on inflammation and oxidative stress in participants with systemic arterial hypertension. A longitudinal double-blind randomized clinical trial will be carried out, involving hypertensive participants for two months.

Read the detailed description

Royal jelly (RG) is considered a superfood that has been used in traditional medicine and dietary supplementation due to its antioxidant, anti-inflammatory, immunomodulatory, and regenerative properties. The antioxidant and anti-inflammatory effects of GR highlight its potential as a natural supplement for the prevention and management of several health conditions. Although in vitro and animal model data are promising, clinical studies are still needed to validate the effects of royal jelly in human populations.

03

Conditions studied

  • Hypertension
  • Cardiovascular Diseases (CVD)
  • Inflammation

Keywords

  • royal jelly
  • inflammation
  • Hypertension
  • cardiovascular diseases
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of stage 1 hypertension
  • Regular treatment for more than 6 months
  • No changes in medication doses during the last 3 months

Exclusion criteria

Exclusion Criteria:

  • diseases
  • Infectious diseases
  • Diabetes
  • Chronic kidney disease
  • Liver disease
  • Cancer
  • AIDS
  • Pregnant women
  • Use of catabolic drugs or antibiotics
  • Use of antioxidant vitamin supplements, prebiotics, probiotics, or synbiotics
  • Habitual intake of royal jelly
  • Allergy to bee stings
  • Acute myocardial infarction (AMI)
  • Stroke (CVA)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
34 participants (estimated)

Study arms

  • Experimental
    Royal Jelly Group

    Participants will receive 2 capsules per day, providing the dosage of 300mg of royal jelly for 2 months (8 weeks).

    Dietary Supplement: Royal Jelly

  • Placebo comparator
    Placebo Group

    The placebo group will receive 2 capsules per day (containing microcrystalline cellulose and magnesium stearate in colored gelatin capsules capable of masking the appearance of the internal content), at the same time for 2 months.

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementRoyal Jelly

    Participants will receive 2 capsules per day, providing the dosage of 300mg of royal jelly for 2 months (8 weeks).

  • Dietary supplementPlacebo

    The placebo group will receive 2 capsules per day (containing microcrystalline cellulose and magnesium stearate in colored gelatin capsules capable of masking the appearance of the internal content), at the same time for 2 months.

06

What researchers measure

Primary outcomes

  1. Change of inflammatory transcripton factor

    Assessment of NFkB expression levels in blood samples collected at baseline and after 8 weeks of supplementation.

    Time frame: Baseline and 8 weeks

Secondary outcomes

  1. Change in interleukin-6 (IL-6) levels

    Assessment of changes in serum interleukin-6 (IL-6) levels after supplementation.

    Time frame: Baseline and 8 weeks

  2. Change in tumor necrosis factor-alpha (TNF-α) levels

    Assessment of changes in serum tumor necrosis factor-alpha (TNF-α) levels after supplementation.

    Time frame: Baseline and 8 weeks

  3. Change in Nrf2 expression

    Assessment of changes in Nrf2 expression after supplementation.

    Time frame: Baseline and 8 weeks

  4. Change in C-reactive protein (CRP) levels

    Assessment of changes in serum C-reactive protein (CRP) levels after supplementation.

    Time frame: Baseline and 8 weeks

  5. Change in antioxidant enzyme activity

    Assessment of changes in antioxidant enzyme activity after supplementation.

    Time frame: Baseline and 8 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Participant data will not be public to other research unless necessary.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Dec 2026, 26 months after the start.

Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 26 months is above that.

Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2025
First posted
Apr 8, 2025
StartActual
Sep 18, 2024
Primary completionEst.
Dec 10, 2026
CompletionEst.
Dec 10, 2026
Last update
May 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06917131
Lead sponsor
Universidade Federal Fluminense
Responsible party
Sponsor
First posted
Apr 8, 2025
Start date
Sep 18, 2024
Primary completion
Dec 10, 2026 (estimated)
Completion
Dec 10, 2026 (estimated)
Last update
May 19, 2026

Study contacts

Denise mafra, PhD
Contact
dmafra30@gmail.com
+5521985683003
Ludmila Cardozo, PhD
principal investigator · Universidade Federal Fluminense

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Royal Jelly

Start the discussion